Zhongsheng Pharmaceutical announced that the RAY1225 injection, an innovative polypeptide drug developed by Zhongsheng Ruichuang, a holding subsidiary of the company, recently completed the enrollment and administration of the first participants in a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial of the safety and efficacy of obesity/overweight participants. RAY1225 injection is an innovative structural polypeptide drug developed by Zhongsheng Ruichuang and has global independent intellectual property rights. It has dual agonizing activity for GLP-1 receptors and GIP receptors. The phase III clinical trial has obtained ethical review approval from the team leader. Zhongsheng Ruichuang actively organized many research centers across the country to participate and launch phase III clinical trials of RAY1225 injection one after another.

Zhongsheng Pharmaceutical announced that the RAY1225 injection, an innovative polypeptide drug developed by Zhongsheng Ruichuang, a holding subsidiary of the company, recently completed the enrollment and administration of the first participants in a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial of the safety and efficacy of obesity/overweight participants. RAY1225 injection is an innovative structural polypeptide drug developed by Zhongsheng Ruichuang and has global independent intellectual property rights. It has dual agonizing activity for GLP-1 receptors and GIP receptors. The phase III clinical trial has obtained ethical review approval from the team leader. Zhongsheng Ruichuang actively organized many research centers across the country to participate and launch phase III clinical trials of RAY1225 injection one after another.